Related Experiment Video

Updated: Jun 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy

Andrea Wahner Hendrickson1, Paul Haluska

  • 1Mayo Clinic College of Medicine, Division of Medical Oncology, Rochester, MN 55905, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2009
PubMed

Insights

Dysregulated insulin-like growth factor (IGF) signaling drives cancer. Targeting the IGF-1 receptor (IGF-1R) shows promise, but understanding sensitivity markers is key to overcoming resistance in cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin-like growth factor (IGF) signaling pathway dysregulation is a key factor in cancer development and progression.
  • IGF signaling contributes to malignant transformation, cell proliferation, survival, migration, and therapeutic resistance.
  • The IGF-1 receptor (IGF-1R) is a significant target for novel anticancer drug development.

Purpose of the Study:

  • To review preclinical and clinical data on factors influencing sensitivity to IGF-targeted cancer therapies.
  • To explore the rationale for combining IGF-1R blockade with other treatments to overcome resistance.
  • To investigate targeting other tyrosine kinases to address intrinsic resistance to IGF-1R therapy.

Main Methods:

  • Review of preclinical and early clinical data on IGF signaling in human cancers.
  • Analysis of molecular determinants of sensitivity to IGF-targeted treatments.
  • Evaluation of strategies for overcoming resistance, including combination therapies.

Main Results:

  • IGF-1R expression alone is insufficient to predict sensitivity to IGF-targeted therapy.
  • Understanding downstream effectors of IGF signaling is crucial for identifying sensitivity markers.
  • Combining IGF-1R blockade with therapies targeting other tyrosine kinases may overcome resistance.

Conclusions:

  • Identifying molecular markers of sensitivity is essential for effective IGF-targeted cancer treatment.
  • Combination strategies are necessary to overcome intrinsic and acquired resistance to IGF-1R inhibition.
  • Targeting related tyrosine kinases like the insulin receptor and EGFR family offers potential to enhance therapeutic outcomes.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: